Apogee Ev To Operating Cash Flow from 2010 to 2026
| APGE Stock | 67.69 0.09 0.13% |
EV To Operating Cash Flow | First Reported 2010-12-31 | Previous Quarter (12.46) | Current Value (13.09) | Quarterly Volatility 18.41083198 |
Check Apogee Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Apogee Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 42 M, Interest Income of 42 M or Depreciation And Amortization of 161.6 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 5.42. Apogee financial statements analysis is a perfect complement when working with Apogee Therapeutics Valuation or Volatility modules.
Apogee | Ev To Operating Cash Flow | Build AI portfolio with Apogee Stock |
Analyzing Apogee Therapeutics's Ev To Operating Cash Flow over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Ev To Operating Cash Flow has evolved provides context for assessing Apogee Therapeutics's current valuation and future prospects.
Latest Apogee Therapeutics' Ev To Operating Cash Flow Growth Pattern
Below is the plot of the Ev To Operating Cash Flow of Apogee Therapeutics Common over the last few years. It is a valuation metric comparing the company's enterprise value to its operating cash flow, indicating how many dollars of EV are generated for each dollar of operating cash flows. Apogee Therapeutics' EV To Operating Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Apogee Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Ev To Operating Cash Flow | 10 Years Trend |
|
Ev To Operating Cash Flow |
| Timeline |
Apogee Ev To Operating Cash Flow Regression Statistics
| Arithmetic Mean | (46.35) | |
| Coefficient Of Variation | (39.72) | |
| Mean Deviation | 15.13 | |
| Median | (56.24) | |
| Standard Deviation | 18.41 | |
| Sample Variance | 338.96 | |
| Range | 43.7843 | |
| R-Value | 0.74 | |
| Mean Square Error | 163.68 | |
| R-Squared | 0.55 | |
| Significance | 0.0007 | |
| Slope | 2.70 | |
| Total Sum of Squares | 5,423 |
Apogee Ev To Operating Cash Flow History
About Apogee Therapeutics Financial Statements
Apogee Therapeutics stakeholders use historical fundamental indicators, such as Apogee Therapeutics' Ev To Operating Cash Flow, to determine how well the company is positioned to perform in the future. Although Apogee Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Apogee Therapeutics' assets and liabilities are reflected in the revenues and expenses on Apogee Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Apogee Therapeutics Common. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| EV To Operating Cash Flow | (12.46) | (13.09) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Apogee Therapeutics is a strong investment it is important to analyze Apogee Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Apogee Therapeutics' future performance. For an informed investment choice regarding Apogee Stock, refer to the following important reports:Check out the analysis of Apogee Therapeutics Correlation against competitors. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Will Biotechnology sector continue expanding? Could Apogee diversify its offerings? Factors like these will boost the valuation of Apogee Therapeutics. If investors know Apogee will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Apogee Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate Apogee Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Apogee Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Apogee Therapeutics' market price to deviate significantly from intrinsic value.
Understanding that Apogee Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Apogee Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Apogee Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.